vomit; booster dose; nausea; This is a spontaneous report from a contactable consumer or other non-healthcare professional (patient) reported in response to non-HCP letter sent. A 51-years-old patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Batch/Lot number and expiry date were not reported), via an unspecified route of administration on an unknown date in 2021 (at the age of 51-years old) as dose 3 (booster), single for COVID-19 immunisation at public health clinic/facility. Vaccine was not administered at private facility. The patient's medical history included photophobia (Entire life worsened) (Aimovig, Sumatriptan), ongoing chronic migraine (12/21 Accident); both were from 01Jan2019, ongoing brain tumor (second tumour growing), tumor removed in May2013, ongoing both rotator cuffs in 2013/2020, both rotator cuffs repaired on an unknown date, ongoing endometriosis from 2018 and need surgery, ongoing osteoarthritis from an unknown date, many surgeries, ongoing fibromyalgia from unknown date. Ongoing anxiety, ongoing PTSD (Post-traumatic stress disorder), ongoing depression, ongoing panic, agarophobia, LDL: High (using crestor); all were from 01Jan2020 and severe concussion from 21Dec2020 (treatment currently). Concomitant medications included elagolix sodium (ORILISSA) taken orally for endometriosis from an unknown date in Jan2021 to ongoing; bupropion hydrochloride (WELLBUTRIN) taken orally for anxiety, post-traumatic stress disorder from an unknown date in Jan2019 to ongoing; alprazolam (XANAX) taken orally for depression, panic disorder from an unknown date in Jan2019 to ongoing; erenumab aooe (AIMOVIG) taken orally shot for chronic migraine from an unknown date in Jan2019 to ongoing; cefixime (FLEXERIL [CEFIXIME]), montelukast sodium (SINGULAIR), esomeprazole sodium (NEXIUM [ESOMEPRAZOLE SODIUM]), probiotics (PROBIOTICS), fish oil (FISH OIL), curcumin (CURCUMIN), colecalciferol (D3), boswellia serrata (BOSWELLIA); all were taken for an unspecified indications, start and stop date were not reported. The patient previously took BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Batch/Lot number: EJ1615, expiry date: not reported), via an intramuscular route of administration in the upper arm on 26Jan2021 at 15:00 (at the age of 51-years old) as dose 1, single and BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Batch/Lot number: EL9267, expiry date: not reported), via an unknown route of administration in the upper arm on 16Feb2021 (at the age of 51-years old) as dose 2, single; both doses for COVID-19 immunisation and experienced nausea, hot and chills. On an unspecified date in 2021, the patient experienced nausea. On 23Aug2021 at 23:00, the patient experienced vomiting. The patient underwent lab tests and procedures which included SPECT (single-photon emission computerized tomography) scan positive on 01Jan2020 (PTSD, Anxiety, Depression, Panic, Agoraphobic), osteoarthritis positive in Jul2021 (bone density), MRI, CT, X-Ray positive in 23Dec2020 (Need surgery-C spine L spine hysterectomy + Possible hip ligament tear). Promethazine was received as a treatment for vomiting. The outcome of the event nausea was unknown and vomiting was recovered in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected. The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.